Relative quantitative expression of hypoxia-inducible factor-1α, -2α and -3α, and vascular endothelial growth factor A in laryngeal carcinoma

Oncology Letters

Volumn 9, Issue 6, 2015, Pages 2879-2885

  Popov, Todor Miroslavov ^a   Goranova, Teodora ^a   Stancheva, Gergana ^a   Kaneva, Radka ^a   Dikov, Tihomir ^a   Chalakov, Ivan ^a   Rangachev, Julian ^a   Konov, Dimitar ^a   Todorov, Spiridon ^a   Stoyanov, Orlin ^a   Mitev, Vanio ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Hypoxia inducible factor 1 ; Hypoxia inducible factor 2 ; Hypoxia inducible factor 3 ; Laryngeal carcinoma; Vascular endothelial growth factor A

Indexed keywords

CATALASE; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IXORA PAVETTA EXTRACT; LIPID PEROXIDASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LIPID ANALYSIS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PHYTOCHEMISTRY; RAT; WEIGHT CHANGE;

EID: 84929998294     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3070     Document Type: Article

References (49)

1. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
2. Wiesener MS, Turley H, Allen WE, et al: Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92: 2260-2268, 1998.
3. Heidbreder M, Fröhlich F, Jöhren O, et al: Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J 17: 1541-1543, 2003.
4. Li QF, Wang XR, Yang YW and Lin H: Hypoxia upregulates hypoxia-inducible factor (HIF)-3alpha expression in lung epithelial cells: Characterization and comparison with HIF-1alpha. Cell Res 16: 548-558, 2006.
5. Pugh CW, O’Rourke JF, Nagao M, et al: Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 272: 11205-11214, 1997.
6. Ikeda E, Achen MG, Breier G and Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270: 19761-19766, 1995.
7. Forsythe JA, Jiang BH, Iyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996.
8. Takeda N, Maemura K, Imai Y,et al: Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res 95: 146-153, 2004.
9. Gerber HP, Condorelli F, Park J and Ferrara N: Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272: 23659-23667, 1997.
10. Marti HH and Risau W: Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 95: 15809-15814, 1998.
11. Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
12. Kertesz N, Wu J, Chen TH, et al: The role of erythropoietin in regulating angiogenesis. Dev Biol 276: 101-110, 2004.
13. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S and Kuck KH: Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64: 326-333, 2002.
14. Morita M, Ohneda O, Yamashita T, et al: HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 22: 1134-1146, 2003.
15. Hirota K and Semenza GL: Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59: 15-26, 2006.
16. Yu J, deMuinck ED, Zhuang Z, et al: Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA 102: 10999-11004, 2005.
17. Coulet F, Nadaud S, Agrapart M and Soubrier F: Identification of hypoxia-response element in the human endothelial nitric-oxide synthase gene promoter. J Biol Chem 278: 46230-46240, 2003.
18. Zhao X, Lu X and Feng Q: Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. Am J Physiol Heart Circ Physiol 283: H2371-H2378, 2002.
19. Maynard MA, Qi H, Chung J, et al: Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278: 11032-11040, 2003.
20. Strauss L, Volland D, Kunkel M and Reichert TE: Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): Possible link between angiogenesis and immune tolerance. Med Sci Monit 11: BR280-BR292, 2005.
21. Alon T, Hemo I, Itin A, Pe’er J, Stone J and Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024-1028, 1995.
22. Gerber HP, Dixit V and Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273: 13313-13316, 1998.
23. Gerber HP, McMurtrey A, Kowalski J, et al: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273: 30336-30343, 1998.
24. Benjamin LE, Golijanin D, Itin A, Pode D and Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165, 1999.
25. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N and Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765-14770, 1996.
26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
27. Scrideli CA, Carlotti CG Jr, Okamoto OK, et al: Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: Identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol 88: 281-291, 2008.
28. Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL and Konstantinova P; Réseau Centre de Ressources Biologiques Foie (French Liver Biobanks Network), France: Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55: 821-832, 2012.
29. International Union Against Cancer: Head and Neck Tumours. In: TNM Classification of Malignant Tumours, 7th Edition. Sobin LH, Gospodarowicz MK & Wittekind C (eds) Wiley-Blackwell, pp39-46, 2009
30. Moreno-Galindo C, Hermsen M, Garcia-Pedrero JM, Fresno MF, Suarez C and Rodrigo JP: p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol 50: 128-134, 2014.
31. Wachters JE, Schrijvers ML, Slagter-Menkema L, Mastik M, de Bock GH, Langendijk JA, et al: Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy. Laryngoscope 123: 2154-2160, 2013.
32. Li DW, Dong P, Wang F, Chen XW, Xu CZ and Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1α. Asian Pac J Cancer Prev 14: 4853-4858, 2013.
33. Xie J, Li DW, Chen XW, Wang F and Dong P: Expression and significance of hypoxia-inducible factor-1α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells. Oncol Lett 6: 232-238, 2013.
34. Wu XH, Chen SP, Mao JY, Ji XX, Yao HT and Zhou SH: Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. Oncol Lett 5: 261-266, 2013.
35. Li DW, Zhou L, Jin B, Xie J and Dong P: Expression and significance of hypoxia-inducible factor-1α and survivin in laryngeal carcinoma tissue and cells. Otolaryngol Head Neck Surg 148: 75-81, 2013.
36. Douglas CM, Bernstein JM, Ormston VE, et al: Lack of prognostic effect of carbonic anhydrase-9, hypoxia inducible factor-1α and bcl-2 in 286 patients with early squamous cell carcinoma of the glottic larynx treated with radiotherapy. Clin Oncol (R Coll Radiol) 25: 59-65, 2013.
37. Wu XH, Lu YF, Hu XD, Mao JY, Ji XX, Yao HT, et al: Expression of hypoxia inducible factor-1α and its significance in laryngeal carcinoma. J Int Med Res 38: 2040-2046, 2010.
38. Moon SY, Chang HW, Roh JL, et al: Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral Oncol 45: 915-919, 2009.
39. Cabanillas R, Rodrigo JP, Secades P, et al: The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer. J Surg Oncol 99: 373-378, 2009.
40. Wildeman MA, Gibcus JH, Hauptmann M, et al: Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? Laryngoscope 119: 316-322, 2009.
41. Kyzas PA, Stefanou D, Batistatou A and Agnantis NJ: Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study. Cancer Lett 225: 297-304, 2005.
42. Yu L, Liu Y and Cui Y: Expression of hypoxia inducible factor-1alpha and its relationship to apoptosis and proliferation in human laryngeal squamous cell carcinoma. J Huazhong Univ Sci Technolog Med Sci. 24: 636-638, 2004.
43. Keith B, Johnson RS and Simon MC: HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22, 2012.
44. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, et al: Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10: 413-423, 2006.
45. Koh MY, Lemos R Jr, Liu X and Powis G: The hypoxia-associated factor switches cells from HIF-1α-to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 71: 4015-4027, 2011.
46. Koh MY and Powis G: Passing the baton: The HIF switch. Trends Biochem Sci 37: 364-372, 2012.
47. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL and Ratcliffe PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686, 2005.
48. Mandriota SJ, Turner KJ, Davies DR, et al: HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1: 459-468, 2002.
49. Fong GH: Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 11: 121-140, 2008.